New hope for kidney disease: common diabetes drugs tested for rare syndrome
NCT ID NCT07214818
Summary
This study is testing whether two drugs, dapagliflozin and empagliflozin, can help control kidney damage in adults with nephrotic syndrome. These drugs are already used for diabetes and heart failure, and researchers want to see if they can reduce protein loss in urine and prevent relapses. The trial will compare the drugs added to standard care against standard care alone over six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Urology & Nephrology Center, Mansoura University
Al Mansurah, Dakahlia Governorate, 35516, Egypt
Conditions
Explore the condition pages connected to this study.